They had both for example: i. Upon either (a) the enrollment of 350 patients in the Phase 3 head and neck cancer study or (b) the closing price of a share of CEL-SCI's common stock on teh primary exchange on which such common stock is then traded exceeds $87.50 for ten consecutive trading days, each Grantee shall earn 25% of teh Awarded Shares.
and so forth ii. full enrollment or $150.00/share iii. end of phase 3 or $225.00/share iv. 1st marketing application or $300.00/share.
I'm not really saying anything ... other than its not the 1st time incentive stock options have been used.
I still believe that currently the trial length combined with IDMC continue is best indication of potential success. Tempered slightly by the trials complexity (primarily the number of countries this thing spans).
Market Data 
Markets 
AI
